Publications by authors named "P U Heuschmann"
Adequate secondary prevention in survivors of intracerebral hemorrhage (ICH) who also have atrial fibrillation (AF) is a long-standing clinical dilemma because these patients are at increased risk of recurrent ICH as well as of ischemic stroke. The efficacy and safety of oral anticoagulation, the standard preventive medication for ischemic stroke patients with AF, in ICH patients with AF are uncertain. PRESTIGE-AF is an international, phase 3b, multi-center, randomized, open, blinded end-point assessment (PROBE) clinical trial that compared the efficacy and safety of direct oral anticoagulants (DOACs) with no DOAC (either no antithrombotic treatment or any antiplatelet drug).
View Article and Find Full Text PDFBackground: We aimed to investigate the prognostic role of β-synuclein in comparison to that of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) for predicting functional outcome after acute ischemic stroke (AIS).
Methods: We measured serum concentrations of β-synuclein, NfL and GFAP 24 h after hospital admission in 213 consecutive patients with moderate-to-severe AIS. We investigated the association between serum biomarkers and radiological/clinical characteristics, 3-months mortality and functional outcome on the modified Rankin Scale (mRS).
Objective: Cushing's syndrome (CS) results in increased cardiovascular (CV) morbidity and mortality. Subtype-specific differences and possible reversibility after biochemical cure are not well investigated.
Design: Prospective cohort study evaluating the CV status in different forms of endogenous cortisol excess.
Article Synopsis
- The BETTER-CARE study is investigating a personalized follow-up care system for breast cancer patients in Germany, focusing on individual needs and risks of long-term therapy side effects.
- It is a cluster-randomized controlled trial involving 30 centers aiming to recruit 1,140 patients, with the primary goal of improving health-related quality of life.
- The pilot phase showed that the approach is feasible, and if successful, it could become a part of routine care in Germany.
Therapeutic drug monitoring in children and adolescents with schizophrenia-spectrum, affective, behavioural, tic and other psychiatric disorders treated with aripiprazole: results of the TDM-VIGIL pharmacovigilance study.
J Neural Transm (Vienna)
November 2024
Article Synopsis
- Aripiprazole, a medication approved for severe mental disorders, is often prescribed off-label to children and adolescents, yet there are no established therapeutic serum level reference ranges for this population.
- A study aimed to investigate the relationship between aripiprazole dosage and serum concentrations in youth, identifying factors like sex, age, and weight that might influence these levels.
- The findings suggested a strong correlation between daily dosage and serum concentration, leading to a preliminary reference range for treating pediatric patients, which indicated potentially better outcomes and fewer side effects when using interquartile ranges for dose determination.